Acarix Named 2025 Digital Innovation Winner by Global Cardiovascular Awards

Recognizing groundbreaking digital, mobile and AI technologies shaping the future of cardiovascular care.

OKLAHOMA CITY, March 14, 2025 /PRNewswire/ -- Acarix, a global leader in AI and acoustics-based cardiac diagnostics, has been awarded the 2025 Digital Innovation Award with an honorable mention for Innovation in Cardiac Imaging at the Global Cardiovascular Awards in London for its breakthrough CADScor® System.

The Digital Innovation Award honors pioneering use of digital, mobile, and AI technologies that are reshaping cardiovascular care. Acarix's CADScor System is revolutionizing early cardiac diagnostics through a non-invasive, AI-driven approach that enables rapid and accurate risk assessment of coronary artery disease (CAD), empowering physicians to identify patients with stable chest pain who require further evaluation.

"We are proud to share that we were awarded the Digital Innovation Award and received an honorable mention for Innovation in Cardiac Imaging, one of only a handful of honorable mentions awarded. It is an honor to be acknowledged among the innovators advancing cardiovascular care globally," said Aamir Mahmood, President and CEO of Acarix. "This award and honorable mention reflects our commitment to integrating advanced AI and acoustic technology to improve patient outcomes. With the CADScor System, clinicians can achieve over 96% certainty in low risk stratification, reducing unnecessary procedures and streamlining patient care pathways, which is a game-changer for both patients and healthcare providers."

The Global Cardiovascular Awards are judged by a distinguished panel of international experts, including CEOs, clinical leaders, and key opinion leaders in cardiovascular and cardiothoracic medicine. Winners are selected through rigorous evaluation of innovations that demonstrate measurable impact on cardiovascular health worldwide.

Founded to spotlight those shaping the future of cardiovascular care, the Global Cardiovascular Awards celebrate outstanding contributions from researchers, clinicians, innovators, and organizations dedicated to advancing prevention, diagnosis, and treatment of cardiovascular disease.

About Acarix
Acarix is a Swedish medical device company pioneering innovative solutions for early risk assessment of coronary artery disease (CAD) at the point of care. The CE-marked and FDA De Novo-cleared CADScor® System is designed for patients experiencing chest pain with suspected CAD, and helps reduce unnecessary, invasive, and costly diagnostic procedures. Used in more than 40,000 patients to date, the CADScor System combines highly sensitive acoustic detection with advanced computational analysis to assess coronary blood flow, and rule out significant CAD, with at least 96% certainty at the point of care.

Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the U.S. (ticker: ACIXF). Carnegie Investment Bank serves as the company's Certified Advisor.

For more information, visit www.acarix.com.

Media Contact:
Ashley Wilson
+1 405 413 5201
[email protected] 

SOURCE Acarix